Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial

Autor: Paul G. Richardson, Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung‐Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi‐Ankrah, Richard Labotka, Robert M. Rifkin, Sagar Lonial, Shaji K. Kumar, S. Vincent Rajkumar, Philippe Moreau

Publikováno v: eJHaem, Vol 4, Iss 4, Pp 995-1005 (2023)

Abstract Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression‐free survival (PFS) and duration of response (DOR) by re

Externí odkaz: https://doaj.org/article/889b8a2ac5cb4c9cba095e412d3f7b15

Supplementary Figures from Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Autor: Wassim Abida, Simon Chowdhury, Tony Golsorkhi, Melanie Dowson, Andrew D. Simmons, Darrin Despain, Simon P. Watkins, Cora N. Sternberg, Laurence E. Krieger, Celestia S. Higano, Karim Fizazi, Axel Heidenreich, Gedske Daugaard, Axel S. Merseburger, Charles J. Ryan, Arif Hussain, Josep M. Piulats, Jingsong Zhang, Eric Voog, Richard M. Bambury, Nicholas J. Vogelzang, Brieuc Sautois, Ray McDermott, Alan H. Bryce, Jeremy Shapiro, David Campbell, Akash Patnaik, Andrea Loehr

Supplementary Figure 1 and 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0623d2eaabec657ce6739813e456e9f
https://doi.org/10.1158/1078-0432.22482885

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Autor: Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld, Fredrik Schjesvold, Anna Nikolayeva, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Gabor Mikala, Laura Rosinol, Tatiana Konstantinova, Anargyros Symeonidis, Moshe Gatt, Arpad Illes, Haifaa Abdulhaq, Moez Dungarwalla, Sebastian Grosicki, Roman Hajek, Xavier Leleu, Alexander Myasnikov, Paul G. Richardson, Irit Avivi, Dries Deeren, Mercedes Gironella, Miguel Teodoro Hernandez-Garcia, Joaquin Martinez Lopez, Muriel Newinger-Porte, Paz Ribas, Olga Samoilova, Eric Voog, Mario Arnao-Herraiz, Estrella Carrillo-Cruz, Paolo Corradini, Jyothi Dodlapati, Miquel Granell Gorrochategui, Shang-Yi Huang, Matthew Jenner, Lionel Karlin, Jin Seok Kim, Agnieszka Kopacz, Nadezhda Medvedeva, Chang-Ki Min, Roberto Mina, Katrin Palk, Ho-Jin Shin, Sang Kyun Sohn, Jason Tache, Achilles Anagnostopoulos, Jose-Maria Arguiñano, Michele Cavo, Joanne Filicko, Margaret Garnes, Janusz Halka, Kathrin Herzog-Tzarfati, Natalia Ipatova, Kihyun Kim, Maria-Theresa Krauth, Irina Kryuchkova, Mihaela Cornelia Lazaroiu, Mario Luppi, Andrei Proydakov, Alessandro Rambaldi, Milda Rudzianskiene, Su-Peng Yeh, Maria Magdalena Alcalá-Peña, Adrian Alegre Amor, Hussain Alizadeh, Maurizio Bendandi, Gillian Brearton, Randall Brown, Jim Cavet, Najib Dally, Miklos Egyed, José Ángel Hernández-Rivas, Ain Kaare, Jean-Michel Karsenti, Janusz Kloczko, William Kreisle, Je-Jung Lee, Sigrid Machherndl-Spandl, Sudhir Manda, Ivan Moiseev, Jan Moreb, Zsolt Nagy, Santosh Nair, Albert Oriol-Rocafiguera, Michael Osswald, Paula Otero-Rodriguez, Valdas Peceliunas, Torben Plesner, Philippe Rey, Giuseppe Rossi, Don Stevens, Celia Suriu, Corrado Tarella, Anke Verlinden, Alain Zannetti

Publikováno v: The Lancet Haematology, 9(2), e98-e110. Lancet Publishing Group
Digital.CSIC. Repositorio Institucional del CSIC
instname

Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc03258e4b4010f40b43625027ef43b
https://doi.org/10.1016/s2352-3026(21)00381-1

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Autor: Sophie Abadie-Lacourtoisie, Thierry Nguyen-Tan-Hon, Jean-Philippe Spano, Olivier Huillard, Nadine Houede, Hakim Mahammedi, Eric Voog, Yohann Loriot, Tifenn Lharidon, Sheik Emambux, Stéphane Culine, Lionnel Geoffrois, Jean-Christophe Eymard, Mounira El Demery, V. Harter, Vesper Trial Investigators, Philippe Barthélémy, Brigitte Laguerre, Yves Allory, Christine Chevreau, Aline Guillot, Florence Joly, Frédéric Di Fiore, Carolina Saldana, Gwenaelle Gravis, Christian Pfister, Werner Hilgers, Camille Serrate, Guilhem Roubaud, Sabine Vieillot, Aude Fléchon, Frederic Rolland

Publikováno v: Clinical Genitourinary Cancer
Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩

Background : Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date. Patients and Methods : In the VESPE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d9aa8d1b02aa6db6c212d2664180052
https://doi.org/10.1016/j.clgc.2021.08.005

Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Autor: Sophie Cereja, Damien Roos-Weil, Laurent Voillat, Marie-Odile Petillon, Véronique Dorvaux, Marie-Lorraine Chretien, Nathalie Meuleman, Hervé Avet-Loiseau, Arthur Bobin, Olivier Fitoussi, Carla Araujo, Murielle Roussel, Eric Voog, Frédérique Kuhnowski, Intergroupe Francophone du Myelome Multiple, Jean Claude Eisenmann, Mourad Tiab, Catherine Humbrecht-Kraut, Thierry Facon, Jean-Valère Malfuson, Brigitte Kolb, Karim Belhadj-Merzoug, Philippe Rodon, Pascal Bourquard, Lionel Karlin, Olivier Decaux, Maeva Kyheng, Valentine Richez, Sophie Rigaudeau, Jamile Frayfer, Xavier Leleu, Philippe Moreau, Arnaud Jaccard, Alain Duhamel, Aurore Perrot, Pascal Lenain, Cyrille Hulin, Cécile Gruchet-Merouze, Jean Fontan, Anna Schmitt, Stéphanie Guidez, Fritz Offner

Publikováno v: Leukemia
Leukemia, 2022, 36 (3), pp.881-884. ⟨10.1038/s41375-021-01415-x⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, ⟨10.1038/s41375-021-01415-x⟩

International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de6cefeb2bdc7ab1443749447bd3dde7
https://hal.science/hal-03476700